Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

[Streptococcus gallolyticus: an opportunistic pathogen associated with colorectal cancer].

Aymeric L, Dramsi S.

Med Sci (Paris). 2018 Oct;34(10):784-787. doi: 10.1051/medsci/2018197. Epub 2018 Nov 19. French. No abstract available.

2.

Significance of Streptococcus gallolyticus subsp. gallolyticus Association With Colorectal Cancer.

Pasquereau-Kotula E, Martins M, Aymeric L, Dramsi S.

Front Microbiol. 2018 Apr 3;9:614. doi: 10.3389/fmicb.2018.00614. eCollection 2018. Review.

3.

Colorectal cancer specific conditions promote Streptococcus gallolyticus gut colonization.

Aymeric L, Donnadieu F, Mulet C, du Merle L, Nigro G, Saffarian A, Bérard M, Poyart C, Robine S, Regnault B, Trieu-Cuot P, Sansonetti PJ, Dramsi S.

Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E283-E291. doi: 10.1073/pnas.1715112115. Epub 2017 Dec 26.

4.

Streptococcus gallolyticus Pil3 Pilus Is Required for Adhesion to Colonic Mucus and for Colonization of Mouse Distal Colon.

Martins M, Aymeric L, du Merle L, Danne C, Robbe-Masselot C, Trieu-Cuot P, Sansonetti P, Dramsi S.

J Infect Dis. 2015 Nov 15;212(10):1646-55. doi: 10.1093/infdis/jiv307. Epub 2015 May 26.

PMID:
26014801
5.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
6.

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Cancer Res. 2014 Jan 15;74(2):436-45. doi: 10.1158/0008-5472.CAN-13-1265. Epub 2013 Dec 3.

7.

Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.

Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, Kroemer G, Zitvogel L.

Cell Death Differ. 2014 Jan;21(1):50-8. doi: 10.1038/cdd.2013.60. Epub 2013 Jun 7.

8.

[Antitumoral immunization during cancer chemotherapy].

Zitvogel L, Hannani D, Aymeric L, Kepp O, Martins I, Kroemer G.

Bull Acad Natl Med. 2012 Jun;196(6):1075-86. Review. French.

PMID:
23596856
9.

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G.

Immunity. 2013 Apr 18;38(4):729-41. doi: 10.1016/j.immuni.2013.03.003. Epub 2013 Apr 4.

10.

Cell-death-associated molecular patterns as determinants of cancer immunogenicity.

Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L.

Antioxid Redox Signal. 2014 Mar 1;20(7):1098-116. doi: 10.1089/ars.2012.5133. Epub 2013 Mar 20. Review.

PMID:
23394620
11.

Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L.

Cancer Res. 2012 Jun 1;72(11):2757-67. doi: 10.1158/0008-5472.CAN-11-3379. Epub 2012 Mar 16.

12.

IL-18 induces PD-1-dependent immunosuppression in cancer.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L.

Cancer Res. 2011 Aug 15;71(16):5393-9. doi: 10.1158/0008-5472.CAN-11-0993. Epub 2011 Jul 1.

13.

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L.

J Exp Med. 2011 Mar 14;208(3):491-503. doi: 10.1084/jem.20100269. Epub 2011 Mar 7. Erratum in: J Exp Med. 2011 Apr 11:208(4):869.

14.

How to improve the immunogenicity of chemotherapy and radiotherapy.

Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, Zitvogel L.

Cancer Metastasis Rev. 2011 Mar;30(1):71-82. doi: 10.1007/s10555-011-9283-2. Review.

PMID:
21298323
15.

Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.

Zitvogel L, Kepp O, Aymeric L, Ma Y, Locher C, Delahaye NF, André F, Kroemer G.

Cancer Res. 2010 Dec 1;70(23):9538-43. doi: 10.1158/0008-5472.CAN-10-1003. Epub 2010 Nov 23. Review.

16.

The dendritic cell-tumor cross-talk in cancer.

Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L.

Curr Opin Immunol. 2011 Feb;23(1):146-52. doi: 10.1016/j.coi.2010.09.008. Epub 2010 Oct 21. Review.

PMID:
20970973
17.

Desirable cell death during anticancer chemotherapy.

Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, Zitvogel L.

Ann N Y Acad Sci. 2010 Oct;1209:99-108. doi: 10.1111/j.1749-6632.2010.05763.x. Review.

PMID:
20958322
18.

Chemotherapy and radiotherapy: cryptic anticancer vaccines.

Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Semin Immunol. 2010 Jun;22(3):113-24. doi: 10.1016/j.smim.2010.03.001. Epub 2010 Apr 18. Review.

PMID:
20403709
19.

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.

Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L.

Cancer Res. 2010 Feb 1;70(3):855-8. doi: 10.1158/0008-5472.CAN-09-3566. Epub 2010 Jan 19. Review.

20.

Immunogenic death of colon cancer cells treated with oxaliplatin.

Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G.

Oncogene. 2010 Jan 28;29(4):482-91. doi: 10.1038/onc.2009.356. Epub 2009 Nov 2.

PMID:
19881547
21.

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Nat Med. 2009 Oct;15(10):1170-8. doi: 10.1038/nm.2028. Epub 2009 Sep 20.

PMID:
19767732

Supplemental Content

Loading ...
Support Center